Actively Recruiting
Phase 2 Randomized Study of Intismeran Autogene with Pembrolizumab and Chemotherapy for First-Line Treatment of Metastatic Squamous NSCLC
Led by Merck Sharp & Dohme LLC · Updated on 2026-10-01
180
Participants Needed
55
Research Sites
96 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether intismeran autogene, given with pembrolizumab and chemotherapy, can improve outcomes for people with metastatic treatment-naive squamous non-small cell lung cancer NSCLC. This study compares the combination of intismeran autogene with pembrolizumab and chemotherapy against a placebo with pembrolizumab and chemotherapy to see if it helps patients live longer without the cancer growing or spreading. The trial is a randomized, double-blind, placebo-controlled Phase 2 study sponsored by Merck Sharp & Dohme LLC. Participants receive treatments in two phases induction and maintenance. During the induction phase, pembrolizumab is given by intravenous infusion every six weeks combined with a platinum-based chemotherapy regimen and either paclitaxel or nab-paclitaxel. Intismeran autogene or placebo injections are administered intramuscularly on specific days during the induction phase. In the maintenance phase, pembrolizumab continues every six weeks, and intismeran autogene or placebo injections are given every three weeks for up to seven doses. Participants will be closely monitored throughout the study with regular assessments including scans, laboratory tests, and evaluations of their cancers response and overall health. The main outcomes measured are progression-free survival and overall survival over approximately 32 to 42 months. Secondary outcomes include response rates, duration of response, and the occurrence of side effects. The study aims to collect comprehensive data to understand the effects and safety of the study treatment combination compared to placebo.
CONDITIONS
Brief Title
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
Research Team
T
Toll Free Number
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here